文献速递肝肾功能剂量调整药物相互作用特殊人群用药

Paritaprevir 的临床药代动力学特征

Clinical Pharmacokinetics of Paritaprevir.
PubMed 文献 · Clin Pharmacokinet · 2017-01-01

本文综述 Paritaprevir 的药代动力学特征。Paritaprevir 主要经 CYP3A4 代谢,与低剂量利托那韦联用可显著延长半衰期、增加暴露量,实现每日一次给药。其药代动力学呈高度可变、非线性特征,轻度至中度肝损伤及轻、中、重度肾损伤包括透析患者无需调整剂量,重度肝损伤暴露量增加。

要点

  • Paritaprevir 经 CYP3A4 代谢,联用低剂量利托那韦可延长半衰期至 5-8 h 并大幅提高暴露量。
  • 轻中度肝损伤及轻至重度肾损伤(含透析)无需调整剂量,重度肝损伤暴露量增加。
  • 日本受试者暴露量高于白种人,但无需调整剂量。

核心结论

  • Paritaprevir 与低剂量利托那韦联用可实现每日一次给药,其药代动力学呈高度可变、非线性特征。
  • 轻度至中度肝损伤及轻、中、重度肾损伤包括透析患者无需调整剂量,重度肝损伤暴露量增加。

研究设计与样本

  • 本文为综述,汇总 Paritaprevir 的临床药代动力学研究数据。

主要发现

  • 联用利托那韦使单剂 Paritaprevir 半衰期从约 3 h 延长至 5-8 h,Tmax 从 2.3 h 倍增至 4.7 h。
  • 联用利托那韦使 Cmax 增加 30 倍、AUC 增加 50 倍、C24 增加 >300 倍。
  • Paritaprevir 呈非线性药代动力学,Cmax 和 AUC 增加幅度大于剂量比例。
  • 有利托那韦存在时,Paritaprevir 主要以原形经胆汁排泄至粪便。
  • 日本受试者暴露量高于白种人,但无需调整剂量;健康受试者与 HCV 感染患者药代动力学相似。

关键数值与推荐

  • 联用利托那韦后单剂 Paritaprevir 半衰期约 5-8 h,Tmax 为 4.7 h。
  • 联用利托那韦后 Cmax 增加 30 倍、AUC 增加 50 倍、C24 增加 >300 倍。
  • 轻度或中度肝损伤及轻、中、重度肾损伤包括透析患者无需调整剂量。
  • 重度肝损伤患者 Paritaprevir 暴露量增加。

临床怎么用

  • Paritaprevir 须与低剂量利托那韦联用以实现每日一次给药。
  • 轻中度肝损伤及轻至重度肾损伤包括透析患者可使用标准剂量。
  • 重度肝损伤患者暴露量增加,需关注。
  • 含利托那韦方案需评估药物相互作用,但可与多种常用合并用药联用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Paritaprevir is a potent hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that is used in combination with other direct-acting antivirals (DAAs) for the treatment of chronic HCV infection. Paritaprevir is primarily metabolized by cytochrome P450 (CYP) 3A4 and is administered with a low dose of ritonavir to achieve drug concentrations suitable for once-daily dosing. Coadministration of paritaprevir with ritonavir increases the half-life of single-dose paritaprevir from approximately 3 h to 5-8 h, doubles the time to maximum plasma concentration (T max) from 2.3 to 4.7 h, and increases exposures 30-fold for maximum observed plasma concentration (C max), 50-fold for area under the plasma concentration-time curve (AUC), and >300-fold for trough concentration (C 24). Paritaprevir displays highly variable, nonlinear pharmacokinetics, with C max and AUC increasing in a greater than dose proportional manner when administered with or without ritonavir. In the presence of ritonavir, paritaprevir is excreted mostly unchanged in feces via biliary excretion. Paritaprevir exposures are higher in Japanese subjects compared with Caucasian subjects; however, no dose adjustment is needed for Japanese patients as the higher exposures are safe and well tolerated. The pharmacokinetic characteristics of paritaprevir are similar between healthy subjects and HCV-infected patients, and are not appreciably altered by mild or moderate hepatic impairment or mild, moderate, or severe renal impairment, including those on dialysis. Paritaprevir exposures are increased in patients with severe hepatic impairment. Although the presence of a low dose of ritonavir in paritaprevir-containing regimens increases the likelihood of drug-drug interactions, results from several drug interaction studies demonstrated that paritaprevir-containing regimens can be coadministered with many comedications that are commonly prescribed in HCV-infected patients.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Menon RM, Polepally AR, Khatri A, et al. Clinical Pharmacokinetics of Paritaprevir. Clin Pharmacokinet. 2017. PMID: 28236252. doi:10.1007/s40262-017-0520-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。